. Juvenile Idiopathic Arthritis. The New England Journal of Medicine. 2025; 393:162-174.
. Genetic Inflammatory Diseases with Ocular Involvement. Genetic Diseases of the Eye. : Oxford University Press (OUP); Oxford University Press (OUP); 2025.
. Severity of acute SARS-CoV-2 infection and risk of new-onset autoimmune disease: A RECOVER initiative study in nationwide U.S. cohorts. Editor, Yon DK. PloS one. 2025; 20:e0324513.
. Clinical, Immunologic, and Genetic Characteristics in Patients With Syndrome of Undifferentiated Recurrent Fevers. Arthritis and Rheumatology. 2025; 77:596-605.
. Candidate Tear-Based Uveitis Biomarkers in Children with JIA Based on Arthritis Activity and Topical Corticosteroid Use. Ocular Immunology and Inflammation (Informa). 2025; 33:603-612.
. Lung Disease in Systemic Juvenile Idiopathic Arthritis: An Atypical Path to Diagnosis. American Journal of Respiratory and Critical Care Medicine. 2025; 211:a7865.
. Experience with T Cell–Depleted Allogeneic HSCT for Refractory sJIA Associated with Lung Disease. 2025; 1.
. Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study. The Lancet. Rheumatology. 2025; 7:e243-e251.
. Multidisciplinary approach to treating complex immune dysregulation disorders: an adaptive model for institutional implementation. Frontiers in Immunology. 2025; 16:1519955.
. Racial Disparities and Achievement of the Low Lupus Disease Activity State: A CARRA Registry Study. Arthritis Care and Research. 2025; 77:38-49.
. Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project. Rheumatology. 2025; 64:32-44.
. Effect of an Electronic Pill Bottle on Hydroxychloroquine Adherence in Pediatric Lupus: Results of a Novel Direct-to-Family Pilot Trial. ACR Open Rheumatology. 2025; 7:e11780.
. Treatment and Visual Outcomes in Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy: A Cohort Study. Ocular Immunology and Inflammation (Informa). 2024; 32:2441-2448.
. Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Pediatric Rheumatology Online Journal. 2024; 22:88.
. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research and Therapy. 2024; 26:125.
. National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned. Annals of Internal Medicine. 2024; 177:1547-1557.
. Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Annals of the Rheumatic Diseases. 2024; 83:1561-1571.
. New discoveries in the genetics and genomics of systemic juvenile idiopathic arthritis. Expert Review of Clinical Immunology. 2024; 20:1053-1064.
. Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology. 2024; 63:SI195-SI206.
. Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:1090-1098.
. Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. Arthritis Care and Research. 2024; 76:328-339.
. The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatric Rheumatology Online Journal. 2024; 21:87.
. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatric Rheumatology Online Journal. 2024; 21:86.
. Genetics of Acquired Cytokine Storm Syndromes : Secondary HLH Genetics. Advances in Experimental Medicine and Biology. 2024; 1448:103-119.
. Effects of the COVID-19 Pandemic in Patients with Systemic Autoinflammatory Diseases. An international survey. 2024; 12.
. COVID-19 and Rheumatic Disease. Firestein Kelley S Textbook of Rheumatology 2 Volume Set. 2024.
. Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis and Rheumatology. 2024; 76:119-129.
. Neutrophils extracellular traps formation may serve as a biomarker for disease activity in oligoarticular juvenile idiopathic arthritis: a pilot study. Arthritis Research and Therapy. 2023; 25:135.
. Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome. Arthritis Research and Therapy. 2023; 25:48.
. Spectrum of severity of multisystem inflammatory syndrome in children: an EHR-based cohort study from the RECOVER program. Scientific Reports. 2023; 13:21005.
. Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. The Journal of Clinical Investigation. 2023; 133:e166741.
. Health Equity Implications of Missing Data Among Youths With Childhood-Onset Systemic Lupus Erythematosus: A Proof-of-Concept Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75:2285-2294.
. Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease. Pediatric Drugs. 2023; 25:649-658.
. Molecular Pathways in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis. Rheumatic Disease Clinics of North America. 2023; 49:895-911.
. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis and Rheumatology. 2023; 75:1714-1732.
. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Annals of the Rheumatic Diseases. 2023; 82:1271-1285.
. Comparison of disease phenotypes and mechanistic insight on causal variants in patients with DADA2. Journal of Allergy and Clinical Immunology. 2023; 152:771-782.
. New developments related to lung complications in pediatric rheumatic disease. Current Opinion in Rheumatology. 2023; 35:273-277.
. Increase in pediatric recurrent fever evaluations during the first year of the COVID-19 pandemic in North America. Frontiers in Pediatrics. 2023; 11:1240242.
. Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry. The Journal of rheumatology. 2023; 50:1047-1057.
. Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care and Research. 2023; 75:1553-1562.
. OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). Annals of the Rheumatic Diseases. 2023; 82:110-111.
. POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL. Annals of the Rheumatic Diseases. 2023; 82:379-380.
. Efficacy and safety of emapalumab in macrophage activation syndrome. Annals of the Rheumatic Diseases. 2023; 82:857-865.
. Impact of the COVID-19 Pandemic on Early Career Investigators in Rheumatology: Recommendations to Address Challenges to Early Research Careers. Arthritis Care and Research. 2023; 75:947-955.
. Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritis-Associated Interstitial Lung Disease. Arthritis Care and Research. 2023; 75:983-988.
. Can Multisystem Inflammatory Syndrome in Children Be Managed in the Outpatient Setting? An EHR-Based Cohort Study From the RECOVER Program. Journal of the Pediatric Infectious Diseases Society. 2023; 12:159-162.
. Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75:715-723.
. Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry. Rheumatology. 2023; 62:804-814.
. Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. The Pediatric Infectious Disease Journal. 2023; 42:119-121.
. Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis. RMD Open. 2023; 9:e002611.
. Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2023; 41:186-194.
. Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. The Journal of rheumatology. 2023; 50:98-106.
. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Annals of the Rheumatic Diseases. 2023; 82:154-160.
. 1119. Covid-19 Mab Use in High-Risk Pediatric Patients. Open Forum Infectious Diseases. 2022; 9:ofac492.958.
. Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology Online Journal. 2022; 20:18.
. Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry. Pediatric Rheumatology Online Journal. 2022; 20:50.
. Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients. The Pediatric Infectious Disease Journal. 2022; 41:985-988.
. Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology Online Journal. 2022; 20:107.
. Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children. JAMA Network Open. 2022; 5:e2241622.
. The Big Bad Wolf: Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus. The Journal of rheumatology. 2022; 49:1082-1084.
. Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis and Rheumatology. 2022; 74:1271-1283.
. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis and Rheumatology. 2022; 74:e1-e20.
. Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA). Rheumatology. 2022; 61:926-935.
. Impact of the Season of Birth on the Development of Juvenile Idiopathic Arthritis in the United States: A Nationwide Registry-based Study. The Journal of rheumatology. 2021; 48:1856-1862.
. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology Online Journal. 2021; 19:131.
. Host genetics of pediatric SARS-CoV-2 COVID-19 and multisystem inflammatory syndrome in children. Current Opinion in Pediatrics. 2021; 33:549-555.
. Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology Online Journal. 2021; 19:122.
. S100 proteins, cytokines, and chemokines as tear biomarkers in children with juvenile idiopathic arthritis-associated uveitis. Ocular Immunology and Inflammation (Informa). 2021; 29:1616-1620.
. Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease. Rheumatic Disease Clinics of North America. 2021; 47:585-606.
. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology. 2021; 73:1898-1909.
. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. Arthritis and Rheumatology. 2021; 73:1910-1920.
. IFN-γ is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome. JCI insight. 2021; 6:e147593.
. miR-181a Mediates Inflammatory Gene Expression After Intracerebral Hemorrhage: An Integrated Analysis of miRNA-seq and mRNA-seq in a Swine ICH Model. Journal of Molecular Neuroscience. 2021; 71:1802-1814.
. Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. The Lancet. Rheumatology. 2021; 3:e574-e584.
. Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. The Journal of rheumatology. 2021; 48:1322-1329.
. Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology. 2021; 73:1334-1340.
. Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. Arthritis Care and Research. 2021; 73:940-946.
. The IL-18/IFNγ axis in systemic JIA and MAS-new answers, more questions. Rheumatology. 2021; 60:3045-3047.
. COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?. Translational Research: the journal of laboratory and clinical medicine. 2021; 232:1-12.
. Repression of CTSG, ELANE and PRTN3-mediated histone H3 proteolytic cleavage promotes monocyte-to-macrophage differentiation. Nature Immunology. 2021; 22:711-722.
. Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. The Pediatric Infectious Disease Journal. 2021; 40:e234-e235.
. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis and Rheumatology. 2021; 73:e13-e29.
. Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics. Current Opinion in Pediatrics. 2021; 33:129-135.
. Preliminary evidence for conserved transcriptional response to adversity in adults with temporomandibular disorder. Pain Reports. 2021; 6:e874.